# Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

## TRIAL

### Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

NCT ID: NCT04802876 Phase: PHASE2 Sponsor: SOLTI Breast Cancer Research Group Status: Active Not Recruiting

## SUMMARY

This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.

## KEY ELIGIBILITY CRITERIA

- 1. Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of PD1 mRNA high-expression (cohort 1, 3) or PD1 mRNA low-expression (cohort 2) determined on the tumor sample will be enrolled in this study. Enrollment of patients \> 75 years of age is allowed after consultation and approval of the study medical monitor.
- 2. Life expectancy \> 3 months as per investigator opinion.
- 3. The participant (or legally acceptable representative if applicable) provides written specific informed consent for the remaining screening tests and study procedures before inclusion in the trial.
- 4. Have measurable disease based on RECIST 1.1 or RANO criteria, as appropriate to tumor type. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- 5. Have radiologic evidence of disease progression or recurrence after the previous oncologic treatment
- 6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 10 days prior to the date of allocation.
- 7. Have adequate organ function. Specimens must be collected within 28 days prior to the start of study treatment.
- 8. Patients could have received a maximum of 3 lines of prior standard of care chemotherapy in the inoperable/metastatic setting.
- 9. Treatment-related toxicities (except alopecia) must d Grade 1 at the time of allocation according to CTCAE version 5.0.
- 1. A Women of childbearing potential who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

Total sites: 1 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT04802876) and public sources. Generated by FindMyCure.ai.